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Abstract
Background: Alzheimer’s disease (AD) is a progressive brain disease with a huge cost to human lives. The impact of the
disease is also a growing concern for the governments of developing countries, in particular due to the increasingly high
number of elderly citizens at risk. Alzheimer’s is the most common form of dementia, a common term for memory loss and
other cognitive impairments. There is no current cure for AD, but there are drug and non-drug based approaches for its
treatment. In general the drug-treatments are directed at slowing the progression of symptoms. They have proved to be
effective in a large group of patients but success is directly correlated with identifying the disease carriers at its early stages.
This justifies the need for timely and accurate forms of diagnosis via molecular means. We report here a 5-protein biomarker
molecular signature that achieves, on average, a 96% total accuracy in predicting clinical AD. The signature is composed of
the abundances of IL-1a, IL-3, EGF, TNF-a and G-CSF.
Methodology/Principal Findings: Our results are based on a recent molecular dataset that has attracted worldwide
attention. Our paper illustrates that improved results can be obtained with the abundance of only five proteins. Our
methodology consisted of the application of an integrative data analysis method. This four step process included: a)
abundance quantization, b) feature selection, c) literature analysis, d) selection of a classifier algorithm which is independent
of the feature selection process. These steps were performed without using any sample of the test datasets. For the first two
steps, we used the application of Fayyad and Irani’s discretization algorithm for selection and quantization, which in turn
creates an instance of the (alpha-beta)-k-Feature Set problem; a numerical solution of this problem led to the selection of
only 10 proteins.
Conclusions/Significance: the previous study has provided an extremely useful dataset for the identification of AD
biomarkers. However, our subsequent analysis also revealed several important facts worth reporting: 1. A 5-protein
signature (which is a subset of the 18-protein signature of Ray et al.) has the same overall performance (when using the
same classifier). 2. Using more than 20 different classifiers available in the widely-used Weka software package, our 5-
protein signature has, on average, a smaller prediction error indicating the independence of the classifier and the
robustness of this set of biomarkers (i.e. 96% accuracy when predicting AD against non-demented control). 3. Using
very simple classifiers, like Simple Logistic or Logistic Model Trees, we have achieved the following results on 92
samples: 100 percent success to predict Alzheimer’s Disease and 92 percent to predict Non Demented Control on the
AD dataset.
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Introduction
Recently, Ray et al. [1] made a significant contribution to the
quest of finding a superior molecular test for an earlier diagnosis of
Alzheimer’s disease (AD). The method appears to have signifi-
cantly improved on the state-of-the-art and, as a consequence,
their results attracted immediate worldwide attention. Using the
abundance of 120 signalling proteins on a training set of 83
archived plasma samples, they produced an 18-protein signature.
On two separate test sets of 92 (‘‘AD’’ Alzheimer’s samples against
control) and 47 (‘‘MCI’’ mild cognitive impairment samples) the
signature was able to show an overall effectiveness of 81% and
91% for AD predictability.
We started this project by analysing the dataset made available
and we are glad to report that we have been able to perfectly
reproduce their mathematical methods and results from the
available datasets. However, our subsequent analysis also pro-
duced several important facts worth reporting: using an integrative
bioinformatics approach, we identified a 6-protein signature that
halves the number of errors in prediction of the previously
proposed signature (on the ‘‘AD’’ dataset.), when using the same
classifier (PAM). A 5-protein signature (which is a subset of the 18-
protein signature of Ray et al.) has the same overall performance.
Finally, using more than 20 different classifiers available in the
widely-used Weka software package [2], our 5-protein signature
has, on average, a smaller prediction error indicating the
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3111independence of the classifier and the robustness of this set of
biomarkers (i.e. 96% accuracy when predicting AD against non-
demented control).
The 6-protein signature is composed of the abundances of IL-
1a, IL-3, IL-6, EGF, TNa and G-CSF. We remark that IL-6 was
not selected by Ray et al. in the preliminary gene selection, and as a
consequence it is not part of their 18-protein signature.
Recognising that the importance of IL-6 as a biomarker for AD
is debatable and that many classifiers do not make use of its
abundance to inform decisions, we also present our results of a 5-
protein signature that ignores IL-6.
Results
Base case–analysis of the performance of randomly
selected signatures
Before reporting our experimental results, it was important to
understand the worst possible performance results that a set of k
proteins can have when they are selected at random (from the
available 120 proteins under study). We showed results of two
experiments that aim at quantifying this. We showed the
classification performance of 20 signatures with 18 proteins
selected at random with a uniform distribution (obviously, we
have selected 18 as is the same number of proteins as the signature
proposed by Ray et al.). Analogously, we performed the same
experiment now constrained to select only six proteins chosen at
random (as we will later present comparative results using
signatures that only employ 6 and 5 proteins).
The two different collections of 20 sets of randomly generated
signatures were chosen using an equal probability for each of the
120 proteins in the set (obviously, not allowing repetitions and
constrained to have either 18 or 6 different proteins in total). For
this experiment, we decided to use a random forests algorithm
(RF) as a base classifier (we are using the algorithm implemented
in [3] for reproducibility purposes), generating 150 trees. As the
chosen classifier also has a stochastic nature, for each signature we
ran 10 experiments with different seeds, and the results we found
are quite interesting.
For these twenty 18-protein signatures the average error over
the 92 samples considered on the ‘‘AD’’ test set, is 15.13 meaning
an 84% effectiveness, see Table 1. For the 6-protein case, an
average error of 30.5% was observed meaning that an expected
lower value of 67% effectiveness was found, see Table 2. With
these results we can infer that the original selection of the 120
genes is quite remarkable for revealing biomarkers for prediction
of clinical AD. Since a random selection with a simple, yet robust,
Table 1. Number of errors from the 18-genes randomly selected signatures on the ‘‘AD’’ validation test set.
Seed Number S18-1 S18-2 S18-3 S18-4 S18-5 S18-6 S18-7 S18-8 S18-9 S18-10
76 18 14 11 18 29 18 11 10 4 10
144 18 15 12 19 25 17 13 11 7 13
121 18 15 10 22 25 19 11 8 7 13
83 17 14 11 21 27 18 13 12 6 15
33 20 18 12 20 27 16 11 11 6 15
51 15 16 11 21 26 17 12 8 6 15
162 15 13 13 20 24 21 14 8 7 13
37 13 14 11 21 29 20 10 9 7 11
136 17 16 13 22 23 20 10 10 5 14
60 18 10 11 17 22 18 10 9 7 15
Average Error 16.9 14.5 11.5 20.1 25.7 18.4 11.5 9.6 6.2 13.4
Average Accuracy 81.6% 84.2% 87.5% 78.2% 72.1% 80.0% 87.5% 89.6% 93.3% 85.4%
Seed Number S18-11 S18-12 S18-13 S18-14 S18-15 S18-16 S18-17 S18-18 S18-19 S18-20
76 17 18 18 16 9 20 7 15 20 11
144 18 22 21 17 9 18 9 16 19 11
121 17 18 20 17 8 15 7 15 22 8
83 16 21 18 16 8 18 10 15 19 13
33 20 22 21 14 8 17 8 15 22 9
51 20 22 22 14 8 20 9 17 22 10
162 19 18 21 16 8 18 7 15 23 10
37 18 21 25 15 7 14 8 15 23 13
136 18 21 17 15 9 18 5 14 23 10
60 19 17 20 13 10 16 9 16 21 12
Average Error 18.2 20 20.3 15.3 8.4 17.4 7.9 15.3 21.4 10.7
Average Accuracy 80.2% 78.3% 77.9% 83.4% 90.9% 81.1% 91.4% 83.4% 76.7% 88.4%
The Random forest algorithm was used as classifier. For each signature 10 runs with different seeds were done. We used the WEKA software implementation, and the
algorithm was allowed to generate 150 trees. The best and worst signatures are highlighted in bold text. In two cases we found signatures that classify above 90%,
comparable with the results of Ray et al. that report on 91% AD predictability as a result of their proposed methodology.
doi:10.1371/journal.pone.0003111.t001
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predictor with only a random selection procedure restricted to
these 120 proteins. Table 3, Figure 1 and Figure 2 resume the
experiment.
It is remarkable that by choosing 18 proteins at random we were
able to obtain a very good signature, at least for this classifier,
under the conditions explained above. Perhaps the reason of
obtaining such good signatures is that a smaller number of
proteins, that all signatures have in common, is all that it is needed
for predictive molecular signature. Figures 1 and 2 show the
relation between the considered signatures with 18 and 6 proteins
and the random ones.
Computational studies: Results obtained with four
different signatures
We report all the results obtained using a set of 24 classifiers
which have been selected from the Weka software suite [3],
aiming at sampling different algorithmic methodologies in
current practice. These classifiers are applied having as input
the four different signatures with the same training set. To ensure
reproducibility of our reported methods, no parameter was
modified from the classifier’s default setting from Weka’s
downloaded code. In this way we were not biasing the
experiment with ad hoc parameter selection and we ensure the
complete reproducibility of our claims. We are also aware that
better results are possible when adjusting the parameters of each
classifier considering only the samples of the training set.
Table 2. Number of errors from the 6-genes randomly selected signatures on the ‘‘AD’’ validation test set.
Seed Number S6-1 S6-2 S6-3 S6-4 S6-5 S6-6 S6-7 S6-8 S6-9 S6-10
76 40 34 20 31 31 32 29 32 24 34
144 40 32 19 34 32 33 30 31 23 33
121 38 37 18 33 35 30 28 32 27 31
83 40 33 19 31 33 34 27 27 24 31
33 41 33 17 35 33 30 27 28 27 29
51 39 33 19 28 34 30 28 28 24 30
162 41 35 19 31 36 34 28 27 26 33
37 40 33 17 32 31 29 27 35 24 32
136 42 36 19 34 34 32 30 34 24 26
60 40 35 17 28 27 31 29 32 23 29
Average Error 40.1 34.1 18.4 31.7 32.6 31.5 28.3 30.6 24.6 30.8
Average Accuracy 56.4% 62.9% 80.0% 65.5% 64.6% 65.8% 69.2% 66.7% 73.3% 66.5%
Seed Number S6-11 S6-12 S6-13 S6-14 S6-15 S6-16 S6-17 S6-18 S6-19 S6-20
76 32 26 30 16 37 39 33 34 32 24
144 30 29 36 17 41 43 32 36 35 24
121 29 25 30 17 41 37 37 34 35 23
83 31 27 31 17 44 35 30 35 33 23
33 32 24 32 17 40 35 35 36 32 23
51 30 25 34 18 41 38 32 35 33 23
162 33 23 30 17 37 33 35 36 35 23
37 31 25 31 17 40 35 32 37 35 22
136 32 29 31 19 43 35 32 39 34 27
60 31 26 33 15 41 36 31 38 32 24
Average Error 31.1 25.9 31.8 17 40.5 36.6 32.9 36 33.6 23.6
Average Accuracy 66.2% 71.8% 65.4% 81.5% 56.0% 60.2% 64.2% 60.9% 63.5% 74.3%
The Random forest algorithm was used as classifier, for each signature 10 runs with different seeds were done. We used the WEKA software implementation, and the
algorithm was allowed to generate 150 trees. The best and worst signatures are highlighted in bold text. This result shows what it is expected, that a 6-signature, when
the biomarkers are randomly chosen, is performing significantly worse than the panel of 18 biomarkers selected by Ray et. al. Now the best result (81.5%) is worse than
the average result of a random 18-signature (86%).
doi:10.1371/journal.pone.0003111.t002





Average Error 15.14 30.59
Best Signature (average) 6.2 17
Worst Signature (average) 25.7 40.5
Standard Deviation 5.36 6.21
Accuracy Average 83.5% 66.7%
The table shows the average results of the 20 random signatures for each size,
also including the best and worst results and the standard deviation. The
accuracy average is calculated considering the error average over the 92
samples of ‘‘AD’’ validation test set.
doi:10.1371/journal.pone.0003111.t003
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PLoS ONE | www.plosone.org 3 September 2008 | Volume 3 | Issue 9 | e3111Figure 1. Histograms of the number of errors of the random forest classifier using 20 randomly selected signatures with 18
proteins. The arrow indicates the results under the same conditions of the 18-protein signature proposed by Ray et al.
doi:10.1371/journal.pone.0003111.g001
Figure 2. Histograms of the number of errors considering the random forest classifier and the 20 randomly selected signatures
with 6 proteins. The arrow indicates the results under the same conditions of our 6-protein signature.
doi:10.1371/journal.pone.0003111.g002
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Protein Name Entrez GeneID
Official gene name provided by HUGO Gene Nomenclature
Committee (HGNC) In signature
18 10 6 5
ANG-2 285 angiopoietin 2 x
CCL5/RANTES 6352 chemokine (C-C motif) ligand 5 x
CCL7/MCP-3 6354 chemokine (C-C motif) ligand 7 x x
CCL15/MIP-1d 6359 chemokine (C-C motif) ligand 15 x x
CCL18/PARC 6362 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) x
CXCL8/IL-8 3576 interleukin 8 x
EGF 1950 epidermal growth factor (beta-urogastrone) x x x x
G-CSF 1440 colony stimulating factor 3 (granulocyte) x x x x
GDNF 2668 glial cell derived neurotrophic factor x
ICAM-1 3383 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor x
IGFBP-6 3489 insulin-like growth factor binding protein 6 x
IL-1a 3552 interleukin 1, alpha x x x x
IL-3 3562 interleukin 3 (colony-stimulating factor, multiple) x x x x
IL-6 3569 interleukin 6 (interferon, beta 2) x x
IL-11 3589 interleukin 11 x x
M-CSF 1435 colony stimulating factor 1 (macrophage) x
PDGF-BB 5155 platelet-derived growth factor beta polypeptide (simian sarcoma viral
(v-sis) oncogene homolog)
xx
TNF-a 7124 tumor necrosis factor (TNF superfamily, member 2) x x x x




Table 5. Report of the results of the 24 classifiers when using the 18-Protein biomarker.
Classifier Grand Total OVERALL (‘‘AD’’+‘‘MCI’’) Test Set ‘‘AD’’ Test Set ‘‘MCI’’
AD Er. NAD Er. AD Er. NAD Er. AD Er. NAD Er.
Dataset size 139 64 75 42 50 22 25
PAM 21 7 14 4 6 3 8
SMO 20 5 15 2 6 3 9
Simple Logistic 25 10 15 5 6 5 9
Logistic 27 11 16 6 7 5 9
Multilayer Perceptron* 21.7 10.1 11.6 4 3.3 6.1 8.3
Bayes Net 27 7 20 3 7 4 13
Naı ¨ve Bayes 23 4 19 1 5 3 14
Naı ¨ve Bayes Simple 23 4 19 1 5 3 14
Naı ¨ve Bayes Up 23 4 19 1 5 3 14
IB1 21 5 16 2 3 3 13
Ibk 21 5 16 2 3 3 13
Kstar 28 5 23 2 11 3 12
LWL 28 15 13 5 3 10 10
AdaBoost 23 9 14 4 3 5 11
ClassViaRegression 28 14 14 5 4 9 10
Decorate* 23.1 7.9 15.2 3.3 5.2 4.6 10
MultiClass Classifier 27 11 16 6 7 5 9
Random Committee* 26.1 10.1 16 4.4 5.5 5.7 10.5
Alzheimer
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Classifier Grand Total OVERALL (‘‘AD’’+‘‘MCI’’) Test Set ‘‘AD’’ Test Set ‘‘MCI’’
AD Er. NAD Er. AD Er. NAD Er. AD Er. NAD Er.
Dataset size 139 64 75 42 50 22 25
j48 24 13 11 3 2 10 9
LMT 25 10 15 5 6 5 9
NBTree 26 13 13 5 4 8 9
Part 25 14 11 7 2 7 9
Random Forest* 24.3 9.3 15 4.1 4 5.2 11
Ordinal Classifier 24 13 11 3 2 10 9
Average 24.34 9.02 15.33 3.66 4.79 5.36 10.53
Agreement (%) 82% 86% 80% 91% 90% 76% 58%
18-Protein Signature (Ray et al.)
doi:10.1371/journal.pone.0003111.t005
Table 6. Report of the results of the 24 classifiers when using the 10-Protein biomarker.
10-Protein Signature
Classifier Grand Total OVERALL (‘‘AD’’+‘‘MCI’’) Test Set ‘‘AD’’ Test Set ‘‘MCI’’
AD Er. NAD Er. AD Er. NAD Er. AD Er. NAD Er.
Dataset size 139 64 75 42 50 22 25
PAM 23 5 18 3 8 2 10
SMO 23 7 16 2 6 5 10
Simple Logistic 23 4 19 1 8 3 11
Logistic 24 6 18 1 9 5 9
Multilayer Perceptron* 21.8 4.9 16.9 1.2 6.9 3.7 10
Bayes Net 28 7 21 1 8 6 13
Naı ¨ve Bayes 31 6 25 2 12 4 13
Naı ¨ve Bayes Simple 31 6 25 2 12 4 13
Naı ¨ve Bayes Up 31 6 25 2 12 4 13
IB1 28 6 22 3 9 3 13
Ibk 28 6 22 3 9 3 13
Kstar 39 3 36 0 18 3 18
LWL 28 15 13 5 3 10 10
AdaBoost 22 4 18 1 8 3 10
ClassViaRegression 23 8 15 1 5 7 10
Decorate* 25.1 6.7 18.4 1.6 8 5.1 10.4
MultiClass Classifier 24 6 18 1 9 5 9
Random Committee* 25.8 9.9 15.9 3.3 6.4 6.6 9.5
j48 22 11 11 3 2 8 9
LMT 37 17 20 8 12 9 8
NBTree 19 13 6 5 3 8 3
Part 21 10 11 3 2 7 9
Random Forest* 23.9 9.4 14.5 2.7 5 6.7 9.5
Ordinal Classifier 22 11 11 3 2 8 9
Average 25.99 7.83 18.15 2.45 7.64 5.38 10.52
Agreement (%) 81% 88% 76% 94% 85% 76% 58%
doi:10.1371/journal.pone.0003111.t006
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6-Protein Signature
Classifier Grand Total OVERALL (‘‘AD’’+‘‘MCI’’) Test Set ‘‘AD’’ Test Set ‘‘MCI’’
AD Er. NAD Er. AD Er. NAD Er. AD Er. NAD Er.
Dataset size 139 64 75 42 50 22 25
PAM 2 0 8 1 21379
SMO 2 0 9 1 12279
Simple Logistic 1 8 4 1 4 0441 0
Logistic 2 1 4 1 70741 0
Multilayer Perceptron* 25.6 3.2 22.4 0.4 9 2.8 13.4
Bayes Net 2 2 8 1 43451 0
Naı ¨ve Bayes 2 3 8 1 52561 0
Naı ¨ve Bayes Simple 2 4 9 1 53561 0
Naı ¨ve Bayes Up 2 3 8 1 52561 0
IB1 33 9 24 3 11 6 13
Ibk 33 9 24 3 11 6 13
Kstar 33 6 27 1 13 5 14
LWL 29 16 13 6 3 10 10
AdaBoost 2 7 1 1 1 63681 0
ClassViaRegression 2 3 1 0 1 33677
Decorate* 24.7 9.8 14.9 2.4 4.8 7.4 10.1
MultiClass Classifier 2 1 4 1 70741 0
Random Committee* 26.6 11.5 15.1 3.1 5.6 8.4 9.5
j48 2 4 1 0 1 42589
LMT 1 8 4 1 4 0441 0
NBTree 2 1 1 0 1 11299
Part 27 13 14 3 5 10 9
Random Forest* 25.6 11.8 13.8 2.6 4.4 9.2 9.4
Ordinal Classifier 2 4 1 0 1 42589
Average 24.44 8.60 15.84 2.02 5.70 6.58 10.14
Agreement (%) 82% 87% 79% 95% 89% 70% 59%
Using this biomarker it is notable the effectiveness of predicting AD on the ‘‘AD’’ test set using simple classifiers as simple logistic or LMT (Logistic Model Tree) or even
the same classifier used in [1] (PAM).
doi:10.1371/journal.pone.0003111.t007
Table 8. Report of the results of the 24 classifiers when using the 5-Protein biomarker.
5-Protein Signature
Classifier Grand Total OVERALL (‘‘AD’’+‘‘MCI’’) Test Set ‘‘AD’’ Test Set ‘‘MCI’’
AD Er. NAD Er. AD Er. NAD Er. AD Er. NAD Er.
Dataset size 139 64 75 42 50 22 25
PAM 2 11 0 1 13279
SMO 1 98 1 12269
Simple Logistic 18 4 14 0441 0
Logistic 2 04 1 60641 0
Multilayer Perceptron* 21.6 5.3 16.3 0.7 5.2 4.6 11.1
Bayes Net 2 14 1 71531 2
Naı ¨ve Bayes 1 95 1 41241 2
Naı ¨ve Bayes Simple 2 05 1 51341 2
Naı ¨ve Bayes Up 1 95 1 41241 2
Alzheimer
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robustness of our methods to discovery biomarkers, by showing
the independence of the signature performance from the selected
classifier.
It is interesting to note that the mathematical model and
algorithms we have used have pointed at Interleukin-6 and
included it in the 10-protein signature. It is well known that IL-
6 with other cytokines have been the subject of many studies of
Table 8. cont.
5-Protein Signature
Classifier Grand Total OVERALL (‘‘AD’’+‘‘MCI’’) Test Set ‘‘AD’’ Test Set ‘‘MCI’’
AD Er. NAD Er. AD Er. NAD Er. AD Er. NAD Er.
Dataset size 139 64 75 42 50 22 25
IB1 3 01 0 2 03771 3
Ibk 3 01 0 2 03771 3
Kstar 2 68 1 83751 1
LWL 29 16 13 6 3 10 10
AdaBoost 31 3 28 1 11 2 17
ClassViaRegression 2 45 1 91741 2
Decorate* 21.8 8.7 13.1 1.7 3.9 7 9.2
MultiClass Classifier 2 04 1 60641 0
Random Committee* 26.1 10.9 15.2 3.1 5.1 7.8 10.1
j48 2 41 0 1 42589
L M T 1 84 1 40441 0
NBTree 2 11 0 1 11299
Part 27 13 14 3 5 10 9
Random Forest* 26.2 12.1 14.1 3.2 4.9 8.9 9.2
Ordinal Classifier 2 41 0 1 42589
Average 23.20 7.71 15.49 1.78 4.75 5.93 10.73
Agreement (%) 83% 88% 79.4% 96% 90% 73% 57%
Removing IL-6 from the biomarker set we have a small gain in predicting AD in both data set, if compared to the 6-protein signature. In this case, the prediction of AD
on the ‘‘AD’’ test set achieves an average of 96% without dropping the accuracy of the prediction of NonAD.
doi:10.1371/journal.pone.0003111.t008
Table 9. Average results for each signature over 24 classifiers.
Size Overall Overall (‘‘AD’’+‘‘MCI’’) Test set ‘‘AD’’ Test set ‘‘MCI’’
AD Er. NAD Er. AD Er. NAD Er. AD Er. NAD Er.
139 64 75 42 50 22 25
18 protein Sig. Error Avg 24.34 9.02 15.33 3.66 4.79 5.36 10.53
Agr % 82% 86% 80% 91% 90% 76% 58%
82% 91% 66%
10 protein Sig. Error Avg 25.98 7.83 18.15 2.45 7.64 5.38 10.52
Agr % 81% 88% 76% 94% 85% 76% 58%
81% 89% 66%
6 protein Sig. Error Avg 24.44 8.60 15.84 2.02 5.70 6.58 10.14
Agr % 82% 87% 79% 95% 89% 70% 59%
82% 92% 64%
5 protein Sig. Error Avg 23.20 7.71 15.49 1.78 4.75 5.93 10.73
Agr % 83% 88% 79% 96% 90% 73% 57%
83% 93% 65%
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bioinformatic approach, described in the next sections, we
draw our attention to a smaller signature. The 6-protein
signature was obtained by the analysis of the protein-relation
graph and interestingly enough, IL-6 is also included in this
new core signature. Finally, in the 5-protein signature, IL-6 is
excluded to provide another comparison and the five proteins
now become a proper subset of the 18 original proteins
uncovered by Ray et al. Table 4 presents the genes included in
each signature, indicating the protein name, Entrez GeneID
and official name.
Tables 5, 6, 7 and 8 show the results of the 24 classifiers for all
the signatures considered. The classifiers marked with a star have a
random component; therefore the average of ten runs with
different seeds is reported. Finally, Tables 9 and 10 summarize the
results.
The results of our 5-protein signature are reported in Table 8.
When considering the ‘‘AD’’ test set, average results (over 24
classifiers) are obtained by the 5-protein signature, 96% when
predicting AD and 90% when predicting non-demented control.
It is also worth mentioning that there are four different
classifiers achieving almost 100% accuracy (i.e. having a
number of errors smaller or equal to 1) for predicting AD on
the ‘‘AD’’ test set. These results are achieved without losing
accuracy when predicting non-demented controls on the same
dataset.
Table 10. The standard deviation of each test is shown on
this table.
Overall
(‘‘AD’’+‘‘MCI’’) Test set AD Test set MCI
AD Er. NAD Er. AD Er. NAD Er. AD Er. NAD Er.
18 protein Sig. 3.580 3.022 1.692 2.087 2.430 1.982
10 protein Sig. 3.546 6.127 1.721 3.893 2.214 2.729
6 protein Sig. 3.165 4.218 1.419 2.798 2.024 1.625
5 protein Sig. 3.520 3.668 1.433 2.175 2.326 1.906
All the signatures show a very similar behaviour with a small standard deviation.
doi:10.1371/journal.pone.0003111.t010
Table 11. Number of errors for each classifier when
considering both test sets together (139 samples).
Method Overall errors
18 10 6 5
Simple Logistic 25 25 18 18
LMT 25 25 18 18
Logistic 27 24 21 20
MultiClass Classifier 27 24 21 20
Bayes Net 27 28 22 21
NBTree 26 23 21 21
Naı ¨ve Bayes 23 30 23 19
Naı ¨ve Bayes Up. 23 30 23 19
ClassViaRegression 28 25 23 24
Naı ¨ve Bayes Simple 23 30 24 20
Kstar 28 41 33 26
Decorate 23.1 28.3 24.7 21.8
SMO 20 23 20 19
Multilayer Perceptron 21.7 21.8 25.6 21.6
PAM 21 22 20 21
Random Committee 26.1 26.3 26.6 26.1
j48 24 24 24 24
Ordinal Class Classifier 24 24 24 24
LWL 28 28 29 29
Random Forest 24.3 24.3 25.6 26.2
Part 25 30 27 27
AdaBoost 23 31 27 31
IB1 21 28 33 30
Ibk 21 28 33 30
Average 24.342 26.821 24.438 23.196
Agreement % 82% 81% 82% 83%
The signature with the best performance on each classifier is highlighted in
bold text.
doi:10.1371/journal.pone.0003111.t011
Table 12. Number of errors for each classifier when
considering the ‘‘AD’’ test set (92 samples).
Method ‘‘AD’’ test set
18 10 6 5
NBTree 9 8 33
Simple Logistic 11 9 44
LMT 11 20 44
Logistic 13 10 7 6
MultiClass Classifier 13 10 7 6
PAM 10 11 4 5
SMO 8 8 44
Naı ¨ve Bayes 6 14 7 3
Naı ¨ve Bayes Up. 6 14 7 3
Bayes Net 10 9 7 6
Decorate 8.5 9.6 7.2 5.6
Naı ¨ve Bayes Simple 6 14 8 4
Kstar 13 18 14 10
Multilayer Perceptron 7.3 8.1 9.4 5.9
Random Committee 9.9 9.7 8.7 8.2
ClassViaRegression 9 6 98
Part 9 5 88
Random Forest 8.1 7.7 7 8.1
LWL 8899
j48 5577
Ordinal Class Classifier 5577
AdaBoost 7 991 2
IB1 5 12 14 10
Ibk 5 12 14 10
Average 8.45 10.09 7.72 6.53
Agreement % 91% 89% 92% 93%
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all the signatures drop at least 30% in accuracy when considering
the ‘‘MCI’’ dataset. This is understandable since the classifiers
have no sample labelled ‘‘MCI’’ in the training set.
The best overall result, considering both test sets, is obtained by
the 6-protein and 5-protein signatures. They present 18 errors and
in both signatures this result is obtained twice when using the
LMT and Simple Logistic classifiers (Tables 7 and 8).
In Table 10, the standard deviations of the number of errors are
almost constant for all signatures, in all datasets. This reinforces
our previous claim, the poor performance of the signatures on the
‘‘MCI’’ dataset is related to the fact that the signatures were not
trained to identify between AD and MCI.
To present the experiment results in another form, we
compared the performance of each signature in each test.
Table 11 presents the comparison between the signatures when
considering all the test sets (‘‘AD’’+‘‘MCI’’) totalling 139 samples.
It is remarkable that the 5-protein signature not only has a better
average performance, but also presents the best result on 16 of the
24 algorithms used for classification (the number of errors
highlighted in bold text indicates the best performance for this
particular classifier).
In Table 12, the same comparison is made but only considering
the ‘‘AD’’ test set. Once again, it is possible to visualize the
performance of the 5-protein signature, obtaining not only the best
average result but also the best individual results, presenting 3
errors on 3 occasions.
Finally, Table 13 presents the same analysis for the ‘‘MCI’’ test
set. In this case the most remarkable observation is the lack of
quality to predict MCI-AD. The improved performance of the
largest signatures is related to the fact that the signatures have
more genes, and because they were not trained to distinguish
between MCI patients, the use of more proteins allows a slightly
better performance. Nevertheless, even the best signature for this
case (a 10-protein signature) presents a poor performance when
compared with the previous results.
Discussion
In conclusion, it is clear that the experiment performed by Ray
et al. provided an extremely useful dataset for the identification of
Alzheimer’s disease biomarkers. We have uncovered a robust 5-
protein signature with near 97% of accuracy to predict AD against
non-demented controls using their data. Our signature has less
than one third of the proteins than the one proposed in the
original paper, and at least the same level of prediction
performance.
The next step on this important quest is to set up an
independent experimental procedure that now considers samples
with mild cognitive impairment (but without AD) in the training
set. We do not agree with the methodology of using a training set
without MCI to select biomarkers to differentiate between AD and
MCI [1]. This has not been done and warrants further
investigation. Only in this way we can uncover useful biomarkers
to discriminate between AD and MCI.
On the positive side, our methods reveal the true predictive
potential of testing for Alzheimer’s disease using this panel of
signalling proteins. We also believe that our methods show
promise and warrant their application in other settings. It is clear
that Alzheimer researchers can benefit directly from our
identification of more robust biomarkers. The method is revealed
to be useful, simple yet very powerful, and warrants its application
in other multifactorial diseases.
Methods
Our methodology consisted of the application of an integrative
data analysis method. We used four steps: a) abundance
quantization, b) feature selection, c) literature analysis, d)
selection of a classifier algorithm which is independent of the
feature selection process. These steps were performed without
using any of the test datasets. For the first two steps, we used the
application of Fayyad and Irani’s discretization algorithm [7] for
selection and quantization, which in turn creates an instance of
the (alpha-beta)-k-Feature Set problem [8–10]. Fayyad and Irani’s
method filtered only 14 out of 120 proteins of the training set
(i.e. those proteins for which no threshold was selected were
filtered out). After quantization, samples 7, 43 (AD, ‘‘Alzheimer’s
Disease’’) and 48 (NDC, ‘‘Nondemented Control’’) of the
training set were ‘‘in conflict’’, which means that they have
quantized values (for all 14 proteins selected) which are the same
although they belong to different classes. These conflicts are then
removed, i.e. the three samples of the training set are eliminated
and we apply our algorithms to the remaining 80 samples of the
training set. Numerical solution of the (alpha-beta)-k-Feature Set
problem led to the selection of only 10 proteins, Table 4. For a
detailed explanation of the methods and other applications,
Table 13. Number of errors for each classifier when
considering the ‘‘MCI’’ test set (47 samples).
Method ‘‘MCI’’ test set
18 10 6 5
ClassViaRegression 19 17 14 16
Bayes Net 17 19 15 15
j48 19 17 17 17
Ordinal Class Classifier 19 17 17 17
Naı ¨ve Bayes 17 17 16 16
Naı ¨ve Bayes Simple 17 17 16 16
Naı ¨ve Bayes Up. 17 17 16 16
Simple Logistic 14 14 14 14
Logistic 14 14 14 14
LWL 20 20 20 20
MultiClass Classifier 14 14 14 14
LMT 14 17 14 14
NBTree 17 11 18 18
Kstar 15 21 19 16
Multilayer Perceptron 14.4 13.7 16.2 15.7
Random Committee 16.2 16.1 17.9 17.9
Decorate 14.6 15.5 17.5 16.2
Random Forest 16.2 16.2 18.6 18.1
AdaBoost 16 13 18 19
Part 16 16 19 19
IB1 16 16 19 20
Ibk 16 16 19 20
SMO 12 15 16 15
PAM 11 12 16 16
Average 16.29 16.11 16.78 16.77
Agreement % 65% 66% 64% 64%
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Figure 3. Classification and prediction of clinical Alzheimer’s diagnosis in subjects with Alzheimer’s disease. (a) An undirected graph,
where each node corresponds a different protein belonging to the 10-protein signature we identified; each edge indicates the existence of a direct
relation as obtained by searching the PubMed database, (using the Pathway Studio software). (b) Identification of the maximum clique of the graph,
uncovering a robust 6-protein signature; each node on the clique has a direct relation with each other. Simple Logistic was used to classify and
predict Alzheimer’s (AD) and non-Alzheimer’s class, in the training set (c), the blinded test set ‘AD’ (d). All the results are shown in a confusion matrix,
for the training set a 10-fold cross-validation was applied 10 times, in both cases Simple Logistic was used with the default parameters of Weka
package. All the p-values were calculated using the Fisher exact test.
doi:10.1371/journal.pone.0003111.g003
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therein [11–13].
To guarantee the reproduction of all our experiments, we use
algorithms from the Weka Package [3] as classifiers. All the
classifiers were used with the default parameters; we are
convinced that better results could be found if adjustments are
made in each classifier (considering only its result over the
training set).
The first signature we uncovered contains 10 proteins, see
Table 4. Using the Pathway Studio software [3], we generated an
undirected graph of the known ‘direct relations’ of these 10
proteins. Each node in the graph corresponds to a protein and an
edge exists if the Pathway Studio software produced a ‘direct
relation’, indicating important association already observed in the
life sciences literature. On this graph we looked for its maximum
clique (Fig. 3a). We denote this graph as G=(V,E). Each vertex in
V has a one-to-one correspondence with a protein. Each pair of
vertices are connected by an edge in E, if and only if, there are
many direct relations between the proteins reported in the
literature. A clique in G is a subset X of V such that its induced
graph G[X] is complete. In other words, we are looking for the
maximum subset of proteins, in which all pairs of proteins already
have a direct relationship identified between them, thus we
consider this set the core of our 10-protein signature (this core has
the 6-proteins listed above, see Fig. 3b).
Our first benchmark test for this 6-protein signature was done
using Simple Logistic (SL) [14], perhaps the simplest classifier from
the Weka software suite. With our 6-protein signature, SL had a
performance of 86% after applying 10 times 10-fold cross-
validation over the training set (Fig. 3c). When considering the
‘‘AD’’ test set, our 6-protein signature with SL was able to make a
classification with 97% of accuracy. For AD samples we achieved
100% positive agreement and for NDC samples a 92% negative
agreement (Fig. 3d).
When using the second test set (labelled ‘‘MCI’’), that includes
samples that had an initial diagnosis of mild cognitive impairment,
the performance of all signatures increases the number of errors. It
is reasonable to expect that our very trimmed classifiers are going
to have some degradation of performance, as they have not been
trained to distinguish confirmed AD samples from those that have
MCI. When using the same signature to differentiate between AD
and other samples of MCI patients, the occurrence of more errors
is an expected outcome (Table 9). In spite of this fact, the overall
performance of all signatures seems very robust.
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